Kala Pharmaceuticals Got Its FDA Approval: What’s Next for the Stock, , on October 30, 2020 at 12:17 am

By
On October 30, 2020
Tags:

There’s a new FDA-approved dry eye treatment on the scene. On Tuesday, the U.S. regulators green-lighted Kala Pharmaceuticals’ (KALA) EYSUVIS 0.25% for the treatment of signs and symptoms of dry eye disease (DED).The go ahead from the FDA makes EYSUVIS the first and only approved corticosteroid for this indication and comes several days ahead of the scheduled October 30 PDUFA. Wedbush analyst Liana Moussatos believes this reflects “both the strength of the regulatory data package” and the “unmet need in this patient population that suffers from a lack of rapid and adequate relief from dry eye flares.”With a plan to increase the sales force from 56 reps to 125 in 2021 and exiting Q3 with $159 million of cash in the coffers – enough to last the company until 3Q22 – Moussatos believes the stage is set for Kala to realize the treatment’s potential.Moussatos estimates dry eye affects 38 million Americans, of which 17 million have been diagnosed and are receiving treatment.However, 90% of these patients are not presently on a prescription and the remaining 10% are given immunomodulatory agents such as RESTASIS®, CEQUA™, and XIIDRA® (roughly 7%) or off-label corticosteroids (roughly 3%).“Consistent with our bullish outlook,” Moussatos concluded, “We view EYSUVIS™ as initially targeting the ~6M patients who are not currently on a prescription and yet complain about chronic flares during office visits (~40%).”Accordingly, Moussatos reiterates an Outperform (i.e. Buy) rating on KALA shares, while increasing the price target from $39 to $47. What’s in it for investors? Enormous upside of 574%. (To watch Moussatos’ track record, click here)While not quite as bullish as the Wedbush analyst, Moussatos’ colleagues see massive upside, too. The analysts’ average price target is $22.60 and implies potential upside of 224%. The stock has a Strong Buy consensus rating, based on 4 Buys and 1 Hold. (See KALA stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.,

Kala Pharmaceuticals Got Its FDA Approval: What’s Next for the StockThere’s a new FDA-approved dry eye treatment on the scene. On Tuesday, the U.S. regulators green-lighted Kala Pharmaceuticals’ (KALA) EYSUVIS 0.25% for the treatment of signs and symptoms of dry eye disease (DED).The go ahead from the FDA makes EYSUVIS the first and only approved corticosteroid for this indication and comes several days ahead of the scheduled October 30 PDUFA. Wedbush analyst Liana Moussatos believes this reflects “both the strength of the regulatory data package” and the “unmet need in this patient population that suffers from a lack of rapid and adequate relief from dry eye flares.”With a plan to increase the sales force from 56 reps to 125 in 2021 and exiting Q3 with $159 million of cash in the coffers – enough to last the company until 3Q22 – Moussatos believes the stage is set for Kala to realize the treatment’s potential.Moussatos estimates dry eye affects 38 million Americans, of which 17 million have been diagnosed and are receiving treatment.However, 90% of these patients are not presently on a prescription and the remaining 10% are given immunomodulatory agents such as RESTASIS®, CEQUA™, and XIIDRA® (roughly 7%) or off-label corticosteroids (roughly 3%).“Consistent with our bullish outlook,” Moussatos concluded, “We view EYSUVIS™ as initially targeting the ~6M patients who are not currently on a prescription and yet complain about chronic flares during office visits (~40%).”Accordingly, Moussatos reiterates an Outperform (i.e. Buy) rating on KALA shares, while increasing the price target from $39 to $47. What’s in it for investors? Enormous upside of 574%. (To watch Moussatos’ track record, click here)While not quite as bullish as the Wedbush analyst, Moussatos’ colleagues see massive upside, too. The analysts’ average price target is $22.60 and implies potential upside of 224%. The stock has a Strong Buy consensus rating, based on 4 Buys and 1 Hold. (See KALA stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

168 Robinson Road,
Capital Tower, Singapore 068912
+65 3105 1295

Taiwan

5th Floor, No. 1-8, Section 5, Zhongxiao East Road, Taipei

Hong Kong

R91, 3rd Floor,
Eton Tower, 8 Hysan Ave.
Causeway Bay, Hong Kong
+852 3002 4462

Australia

44 Martin Place, Sydney 2000 Australia
+02 8319 3232

Indonesia

Millennium Centennial Center, 38th Floor, Jl. Jend. Sudirman Kav. 25
Jakarta 12920, Indonesia

Market Coverage